Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback